Sinopharm Group Co. Ltd.
SHTDY | OTC
$10.41
+$0.10 (+0.97%)
Nov 2, 2026, 11:43 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 568.02B | 575.17B | 575.82B | 584.51B | 590.35B | 596.57B | 446.72B | 407.24B | 533.4B | 521.05B | 501.77B |
Cost of Revenue | 528.11B | 533.07B | 532.74B | 540.25B | 543.16B | 548.06B | 397.67B | 359.8B | 488.28B | 477B | 458.1B |
Gross Profit | 39.91B | 42.1B | 43.09B | 44.26B | 47.18B | 48.51B | 49.05B | 47.43B | 45.12B | 44.05B | 43.67B |
Operating Income | 16.76B | 15.73B | 15.11B | 16.19B | 18.6B | 20.21B | 23.08B | 22.76B | 21.42B | 20.98B | 20.59B |
Interest Income | 402.08M | 515.05M | 520.57M | 668.83M | -356.46M | 526.21M | 1.64B | 1.81B | 3.16B | 3.15B | 2.85B |
Pretax Income | 14.44B | 14.79B | 13.6B | 14B | 18.24B | 19.51B | 14.84B | 13.98B | 17.29B | 17B | 17.1B |
Net Income | 7.05B | 7.15B | 6.8B | 7.05B | 8.65B | 9.05B | 8.94B | 8.53B | 7.87B | 7.76B | 7.87B |
Selling & General & Admin | 22.41B | 24.49B | 25.69B | 25.57B | 25.47B | 26.78B | 21.5B | 20.19B | 24.28B | 23.66B | 23.65B |
Research & Development | n/a | 123.36M | 123.36M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | 742.34M | 1.75B | 2.16B | 2.49B | 3.46B | 2.12B | 129.94B | 129.93B | -27.36M | -15.29M | 211.19K |
Operating Expenses | 23.15B | 26.37B | 27.98B | 28.07B | 28.92B | 28.3B | 150.85B | 149.93B | 24.67B | 23.89B | 23.72B |
Interest Expense | 2.18B | 1.68B | 1.59B | 2.1B | 965.5M | n/a | 1.27B | 1.27B | n/a | n/a | n/a |
Selling & Marketing Expenses | 8.34B | 16.18B | 16.52B | 17.16B | 17.52B | 17.47B | 13.23B | 12.58B | 15.61B | 15.44B | 15.49B |
Cost & Expenses | 551.26B | 559.43B | 560.72B | 568.32B | 570.62B | 574.9B | 428.53B | 389.74B | 512.96B | 500.89B | 481.82B |
Income Tax Expense | 3.83B | 3.96B | 3.75B | 3.58B | 4.23B | 4.5B | 3.41B | 3.22B | 4.03B | 3.94B | 3.78B |
Shares Outstanding (Basic) | 3.12B | 3.12B | 3.12B | 3.11B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B |
Shares Outstanding (Diluted) | 3.12B | 3.12B | 3.12B | 3.11B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B |
EPS (Basic) | 2.25 | 2.29 | 2.18 | 2.26 | 2.78 | 2.91 | 2.87 | 2.74 | 2.53 | 2.49 | 2.52 |
EPS (Diluted) | 2.25 | 2.29 | 2.18 | 2.26 | 2.78 | 2.91 | 2.87 | 2.74 | 2.53 | 2.49 | 2.52 |
EBITDA | 20.57B | 20.37B | 20.58B | 20.17B | 23.02B | 24.4B | 20.58B | 20.22B | 23.39B | 22.9B | 22.54B |
EBIT | 17.69B | 17.22B | 17.14B | 17.82B | 20.86B | 22.32B | 17.07B | 16.75B | 21.42B | 20.98B | 20.59B |
Depreciation & Amortization | 2.88B | 3.15B | 3.44B | 2.36B | 2.16B | 2.09B | 3.5B | 3.47B | 1.97B | 1.91B | 1.95B |
Add to Watchlist
Select watchlists to add or remove SHTDY